Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor

Abstract Ligand-activated signaling through the type 1 insulin-like growth factor receptor (IGF1R) is implicated in many physiological processes ranging from normal human growth to cancer proliferation and metastasis. IGF1R has also emerged as a target for receptor-mediated transcytosis, a transport...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joey Sheff, Ping Wang, Ping Xu, Melanie Arbour, Luke Masson, Henk van Faassen, Greg Hussack, Kristin Kemmerich, Eric Brunette, Danica Stanimirovic, Jennifer J. Hill, John Kelly, Feng Ni
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/abc8b420f9a841a1ad3480689cc4f109
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:abc8b420f9a841a1ad3480689cc4f109
record_format dspace
spelling oai:doaj.org-article:abc8b420f9a841a1ad3480689cc4f1092021-12-02T12:11:28ZDefining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor10.1038/s41598-021-83198-w2045-2322https://doaj.org/article/abc8b420f9a841a1ad3480689cc4f1092021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83198-whttps://doaj.org/toc/2045-2322Abstract Ligand-activated signaling through the type 1 insulin-like growth factor receptor (IGF1R) is implicated in many physiological processes ranging from normal human growth to cancer proliferation and metastasis. IGF1R has also emerged as a target for receptor-mediated transcytosis, a transport phenomenon that can be exploited to shuttle biotherapeutics across the blood–brain barrier (BBB). We employed differential hydrogen–deuterium exchange mass spectrometry (HDX-MS) and nuclear magnetic resonance (NMR) to characterize the interactions of the IGF1R ectodomain with a recently discovered BBB-crossing single-domain antibody (sdAb), VHH-IR5, in comparison with IGF-1 binding. HDX-MS confirmed that IGF-1 induced global conformational shifts in the L1/FnIII-1/-2 domains and α-CT helix of IGF1R. In contrast, the VHH-IR5 sdAb-mediated changes in conformational dynamics were limited to the α-CT helix and its immediate vicinity (L1 domain). High-resolution NMR spectroscopy titration data and linear peptide scanning demonstrated that VHH-IR5 has high-affinity binding interactions with a peptide sequence around the C-terminal region of the α-CT helix. Taken together, these results define a core linear epitope for VHH-IR5 within the α-CT helix, overlapping the IGF-1 binding site, and suggest a potential role for the α-CT helix in sdAb-mediated transcytosis.Joey SheffPing WangPing XuMelanie ArbourLuke MassonHenk van FaassenGreg HussackKristin KemmerichEric BrunetteDanica StanimirovicJennifer J. HillJohn KellyFeng NiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Joey Sheff
Ping Wang
Ping Xu
Melanie Arbour
Luke Masson
Henk van Faassen
Greg Hussack
Kristin Kemmerich
Eric Brunette
Danica Stanimirovic
Jennifer J. Hill
John Kelly
Feng Ni
Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
description Abstract Ligand-activated signaling through the type 1 insulin-like growth factor receptor (IGF1R) is implicated in many physiological processes ranging from normal human growth to cancer proliferation and metastasis. IGF1R has also emerged as a target for receptor-mediated transcytosis, a transport phenomenon that can be exploited to shuttle biotherapeutics across the blood–brain barrier (BBB). We employed differential hydrogen–deuterium exchange mass spectrometry (HDX-MS) and nuclear magnetic resonance (NMR) to characterize the interactions of the IGF1R ectodomain with a recently discovered BBB-crossing single-domain antibody (sdAb), VHH-IR5, in comparison with IGF-1 binding. HDX-MS confirmed that IGF-1 induced global conformational shifts in the L1/FnIII-1/-2 domains and α-CT helix of IGF1R. In contrast, the VHH-IR5 sdAb-mediated changes in conformational dynamics were limited to the α-CT helix and its immediate vicinity (L1 domain). High-resolution NMR spectroscopy titration data and linear peptide scanning demonstrated that VHH-IR5 has high-affinity binding interactions with a peptide sequence around the C-terminal region of the α-CT helix. Taken together, these results define a core linear epitope for VHH-IR5 within the α-CT helix, overlapping the IGF-1 binding site, and suggest a potential role for the α-CT helix in sdAb-mediated transcytosis.
format article
author Joey Sheff
Ping Wang
Ping Xu
Melanie Arbour
Luke Masson
Henk van Faassen
Greg Hussack
Kristin Kemmerich
Eric Brunette
Danica Stanimirovic
Jennifer J. Hill
John Kelly
Feng Ni
author_facet Joey Sheff
Ping Wang
Ping Xu
Melanie Arbour
Luke Masson
Henk van Faassen
Greg Hussack
Kristin Kemmerich
Eric Brunette
Danica Stanimirovic
Jennifer J. Hill
John Kelly
Feng Ni
author_sort Joey Sheff
title Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
title_short Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
title_full Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
title_fullStr Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
title_full_unstemmed Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
title_sort defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/abc8b420f9a841a1ad3480689cc4f109
work_keys_str_mv AT joeysheff definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT pingwang definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT pingxu definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT melaniearbour definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT lukemasson definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT henkvanfaassen definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT greghussack definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT kristinkemmerich definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT ericbrunette definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT danicastanimirovic definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT jenniferjhill definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT johnkelly definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
AT fengni definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor
_version_ 1718394649103564800